LGVN

Longeveron Class A (LGVN)

About Longeveron Class A (LGVN)

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Details

Daily high

$1.85

Daily low

$1.76

Price at open

$1.80

52 Week High

$23.90

52 Week Low

$0.77

Market cap

11.7M

Dividend yield

0.00%

Volume

458,840

Avg. volume

434,973

P/E ratio

-.21

Longeveron Class A News